

ZELTIA NEWS

GENOMICA obtains approval in Brazil to market its CLART® innovative in vitro diagnostic platform

- **CLART® Strip is the technology used in the CLART® product line.**
- **GENOMICA will market its products in Brazil through local partner bioMérieux, which is also specialised in diagnostics *in vitro*.**

Madrid, 24 March 2011: GENOMICA, the Grupo Zeltia (ZEL.MC) company that is a leader in clinical diagnostics and genetic fingerprinting has obtained authorisation from Brazil's National Health Surveillance Agency (Anvisa) to market CLART® HPV2, CLART® PneumoVir and CLART® ENTHERPEX and its CAR microarray reader in Brazil.

The CLART® Strip (CS) platform is based on a very simple, convenient and effective approach under which a low density (3x3) microarray is printed in the bottom of a microtitre well (CS), which simplifies hybridisation and visualisation compared with traditional microarray systems. The CS technology allows simultaneous detection of multiple molecular markers of use in diagnostics, prognostics and pharmacogenomics and the inclusion of the necessary controls to ensure the reliability of the results that are obtained.

GENOMICA will market its products in Brazil through local partner bioMérieux, a company specialised in diagnostics *in vitro* that develops, manufactures and markets diagnostic systems (reagents, tools and software) for medical and industrial use.



Dr. Rosario Cospedal, General Manager of GENOMICA: "obtaining marketing authorisation for CLART® in Brazil is a milestone and represents a major advance in the company's internationalisation process. GENOMICA sells its products in more than 30 countries and it plans to expand internationally to become a leader in molecular diagnostics and personalised medicine".

Dr. Patrice Ancillion, General Manager of bioMérieux Brasil: "through our alliance with GENOMICA, we will be able to offer our customers an innovative range of quality products which dovetails with our strategic vision. In the last few months, we have detected promising interest among our customers and local dealers."

About Zeltia

Zeltia S.A. is a world-leading biopharmaceutical company specialised in the development of marine-based drugs for use in oncology and central nervous system illnesses. Grupo Zeltia consists mainly of the following companies: PharmaMar, the world-leading biotechnology company in advancing cancer care through the discovery and development of innovative marine-derived medicines; Noscira, a biotech firm focused on discovering and developing new drugs against Alzheimer's disease and other neurodegenerative diseases of the central nervous system; Genómica, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and a chemical division comprising Zelnova and Xylazel, two highly profitable companies that are leaders in their respective market segments.

About GENOMICA

GENOMICA S.A.U. is Spain's leading molecular diagnostics company. Founded in 1990, the company is based in the Madrid region. It is wholly owned by Zeltia. The company's mission is to apply quality and automation to improve the current approach to molecular diagnostics in the life sciences. The company's main goal is to lead the Spanish market in genomic applications and expand internationally in the area of molecular diagnostics and personalised medicine by designing, developing and selling new diagnostic applications based on the CLART® (CLINICAL ARRAY TECHNOLOGY) platform. GENOMICA has developed a diagnostic test for human papilloma virus (associated with cervical cancer), a system for diagnosing respiratory viruses, and a method for detecting human herpes virus; it also markets a test for detecting genetic markers associated with response to therapy. GENOMICA is a leading supplier of genetic identification services in legal and forensic medicine and in technology transfer (turnkey laboratories). <http://www.genomica.es/>

For more information, contact Zeltia at +34 91 444 4500.

This note is also available in the "News" section of the Zeltia (www.zeltia.com) and GENOMICA (www.genomica.es) websites